Phase 1 clinical trial evaluating the safety, tolerability, and immunogenicity of AST-021p, a novel cancer vaccine targeting HSP90-derived epitopes in advanced solid tumor patients (CornerStone-002)

AST-021p - Aston Sci.

E. Kang 1; K. Lee 1; I. Kim 2; J. Kim 3; J. Kim 3; S. Lee 3; J. Lee 3; K. Shin 2; S. Park 2; J. Kim 2; H. Shin 4; K. Park3

Mar 6, 2024